A lzheimer's disease (AD) is characterized by the abnormal accumulation of tau and Aβ proteins, a process that is known to affect specific neuronal systems. In fact, it has been consistently shown that both of these pathological hallmarks of AD affect specific large-scale circuits, whereas other circuits remain spared or become disrupted later in the disease [1] [2] [3] [4] [5] . Moreover, genetic population studies have shown that AD can be genetically determined, such as in familial forms of AD characterized by APP (encoding amyloid precursor protein), PSEN1 (encoding presenilin 1) or PSEN2 mutations, or genetically predisposed, such as in late-onset sporadic AD, which is highly associated with apolipoprotein E (APOE) ε 4 allele positivity (and, to a lesser extent, to polygenic associations of ~20 genes thus far described in the literature [6] [7] [8] [9] [10] [11] ). However, it is still unknown whether and how these genetic factors confer vulnerability to the distinct spread of AD pathology across specific neuronal circuits in the aging brain. Several reasons can be speculated for this neglect. Until now, we have lacked the analytical tools to determine in vivo longitudinal propagation patterns of tau and Aβ deposits in the human brain. This has precluded the detection of pathways related to the progression of AD pathology in cerebral tissue, as well as the investigation of genetic features potentially related with hypothesized pathways. Second, until the advent of microarray data covering the protein-coding transcriptome of the entire human cerebral tissue (Allen Human Brain Atlas (AHBA)) 12, 13 , we have lacked high-spatial-resolution data for investigating gene expression levels associated with cortical anatomy. Third, we have lacked research approaches for combining findings from in vivo tau and Aβ propagation topologies with genetic profiles of cerebral circuits. Overall, the characterization of the neurogenetic basis of the cortical spreading of AD pathology would provide a critical understanding of how genes interact with AD pathology and neurodegeneration 14 . AD dementia is a major public health challenge and one that poses an even greater threat as the current population ages. Recently, preclinical stages of AD have been a major topic of investigation, motivated by the acknowledgment that the pathophysiological process begins decades before any cognitive decline appears 15 . Thus, studying the pathways in which tau and Aβ spreads early on, as well as studying the genetic underpinnings of the respective spreading pathways, is crucial for advancing diagnostic accuracy as well as for enabling early disease-modifying interventions. Following that rationale, in this study, we hypothesized that specific gene expression profiles in brain tissue sustain the propagation selectivity of AD pathology along specific neuronal systems. To that end, we first focused on the identification of in vivo propagation pathways of tau and Aβ deposits in a longitudinal sample of healthy adult study participants (SP) from the Harvard Aging Brain Study (HABS) [16] [17] [18] [19] . We developed graph theory metrics to detect the main cortical routes of pathology progression at the group level using positron emission tomography (PET) imaging, and built a novel staging approach to investigate subject-level pathway profiles of spreading of pathology and their relationship with neuropsychological and cognitive profiles. Last, using the AHBA, we characterized regional gene expression profiles associated with tau and Aβ PET pathology progression patterns across the cerebral cortex to better understand at the neural systems level the vulnerability that AD-related genetic profiles confer on AD pathology progression in the human brain.
A lzheimer's disease (AD) is characterized by the abnormal accumulation of tau and Aβ proteins, a process that is known to affect specific neuronal systems. In fact, it has been consistently shown that both of these pathological hallmarks of AD affect specific large-scale circuits, whereas other circuits remain spared or become disrupted later in the disease [1] [2] [3] [4] [5] . Moreover, genetic population studies have shown that AD can be genetically determined, such as in familial forms of AD characterized by APP (encoding amyloid precursor protein), PSEN1 (encoding presenilin 1) or PSEN2 mutations, or genetically predisposed, such as in late-onset sporadic AD, which is highly associated with apolipoprotein E (APOE) ε 4 allele positivity (and, to a lesser extent, to polygenic associations of ~20 genes thus far described in the literature [6] [7] [8] [9] [10] [11] ). However, it is still unknown whether and how these genetic factors confer vulnerability to the distinct spread of AD pathology across specific neuronal circuits in the aging brain. Several reasons can be speculated for this neglect. Until now, we have lacked the analytical tools to determine in vivo longitudinal propagation patterns of tau and Aβ deposits in the human brain. This has precluded the detection of pathways related to the progression of AD pathology in cerebral tissue, as well as the investigation of genetic features potentially related with hypothesized pathways. Second, until the advent of microarray data covering the protein-coding transcriptome of the entire human cerebral tissue (Allen Human Brain Atlas (AHBA)) 12, 13 , we have lacked high-spatial-resolution data for investigating gene expression levels associated with cortical anatomy. Third, we have lacked research approaches for combining findings from in vivo tau and Aβ propagation topologies with genetic profiles of cerebral circuits. Overall, the characterization of the neurogenetic basis of the cortical spreading of AD pathology would provide a critical understanding of how genes interact with AD pathology and neurodegeneration 14 . AD dementia is a major public health challenge and one that poses an even greater threat as the current population ages. Recently, preclinical stages of AD have been a major topic of investigation, motivated by the acknowledgment that the pathophysiological process begins decades before any cognitive decline appears 15 . Thus, studying the pathways in which tau and Aβ spreads early on, as well as studying the genetic underpinnings of the respective spreading pathways, is crucial for advancing diagnostic accuracy as well as for enabling early disease-modifying interventions. Following that rationale, in this study, we hypothesized that specific gene expression profiles in brain tissue sustain the propagation selectivity of AD pathology along specific neuronal systems. To that end, we first focused on the identification of in vivo propagation pathways of tau and Aβ deposits in a longitudinal sample of healthy adult study participants (SP) from the Harvard Aging Brain Study (HABS) [16] [17] [18] [19] . We developed graph theory metrics to detect the main cortical routes of pathology progression at the group level using positron emission tomography (PET) imaging, and built a novel staging approach to investigate subject-level pathway profiles of spreading of pathology and their relationship with neuropsychological and cognitive profiles. Last, using the AHBA, we characterized regional gene expression profiles associated with tau and Aβ PET pathology progression patterns across the cerebral cortex to better understand at the neural systems level the vulnerability that AD-related genetic profiles confer on AD pathology progression in the human brain.
data from HABS participants (n = 88; Supplementary Table 1) , we detected distinct propagation pathways for tau and Aβ accumulation. We developed a graph theory approach, named directional graph theory regression (DGTR; Supplementary Fig. 1 ), to predict at the cross-sectional level and corroborate at the longitudinal level, brain tau and Aβ pathology changes as imaged by in vivo PET imaging in samples of healthy adult individuals. By doing so, the crosssectional tau findings predicted graph-based connectivity between the temporal region of interest and the anterior and inferior part of the temporal lobe, as well as midline frontal regions, such as the orbitofrontal cortex (Fig. 1a) . The longitudinal tau findings not only confirmed anterior and inferior temporal lobe and midline frontal regions as spatiotemporal targets for tau propagation but additionally revealed that these pathways also extend from the temporal lobe into the posterior cingulate cortex (PCC) and precuneus (Fig. 1b) . Overall, we found a high spatial association between cross-sectionally predicted and longitudinally observed network propagation of tau (scatter plot in Fig. 1 ; r = 0.599). Analogous results were obtained with a replication data set (n = 24 HABS healthy adults), both with and without partial volume correction (PVC; Supplementary Fig. 2 ). We also detected propagation pathways of Aβ , in which the PCC was related with distributed regions in the lateral frontoparietal, midline frontal and precuneus regions at the cross-sectional level (Fig. 1c) . The longitudinal findings confirmed that Aβ predominantly spreads toward neighboring posterior and lateral parietal lobe regions (Fig. 1d ). Analogous to tau propagation, we found a high spatial association between cross-sectionally predicted and longitudinally observed network propagation of Aβ (scatter plot in Fig. 1 ; r = 0.623). Similar results were obtained with the replication data set, both with and without PVC ( Supplementary Fig. 2 ).
Hubs of pathology propagation of tau and amyloid. Next, we detected brain regions where a disproportionate number of propagation routes converged in our longitudinal sample, either as outdegree hubs (regions for which the signal in time 1 explained the signal of many other regions in time 2 (see the small-network diagram in Fig. 2) ) or in-degree hubs (regions in which the signal in time 2 is explained by the signal of many other regions in time 1 (see the small-network diagram in Fig. 2) ) of pathology. On the one hand, we found that tau out-degree hubs were mostly located in the medial temporal lobe, including the parahippocampus and the inferior temporal neocortex (top-left cortical maps in Fig. 2a) , whereas tau in-degree hubs involved the mid-cingulate cortex/PCC and some frontal dorsal areas (bottom-left cortical maps in Fig. 2a) . The aggregation display showed that tau out-degree hubs and indegree hubs were distantly located without overlap (cortical overlap map in Fig. 2a ). On the other hand, we found that Aβ out-degree hubs were mostly found in angular and supramarginal gyri, the PCC and the mid/superior frontal regions (top-right cortical maps in Fig. 2b ), whereas Aβ in-degree hubs were located in the precuneus, left inferior and superior parietal cortex and the confluence between the superior frontal gyrus and the supplementary motor area (bottom-right cortical maps in Fig. 2b ). The aggregation display showed that Aβ out-degree hubs and in-degree hubs display a high degree of overlap in the angular gyrus and some degree of overlap at the junction between the PCC and the precuneus (cortical overlap map in Fig. 2b ).
Tau and amyloid propagation-based method in individual subjects. Next, we used the main out-degree and in-degree propagation pathways obtained in the DGTR analysis at the group level to characterize individual tau and amyloid deposition profiles in the SP sample (n = 64; SP with complete neuropsychological assessment), as well as in an additional sample of AD/mild cognitive impairment (MCI) individuals (n = 19), both from our cross-sectional data (Fig. 3) . To build this propagation-based method, we extracted the main tau propagation routes-seven in total: mid-cingulate cortex/PCC, bilateral dorsal frontal, bilateral temporal pole, bilateral medial/ inferior temporal-and the main Aβ propagation routes-six in total: PCC, mid/superior frontal, bilateral inferior parietal and lateral temporal-based on the out-degree and in-degree hubs maps (see the arrows in the polar plots of Fig. 3a) . Each of these tau and Aβ propagation routes showed significant differences between elderly subjects and AD groups (violin plots in Fig. 3a) . Moreover, using this propagation-based approach, we found that lower global cognition and lower memory scores were associated to specific tau pathways in this cross-sectional data, particularly deposits involving the temporal lobe (see the correlation matrix and scatter plots in Fig. 3b) , with no associations found for executive functions. Propagation-based analysis of Aβ routes was not associated with any cognitive measure.
Brain colocalization of in vivo propagation patterns and Allen gene expression data. Among the 21 pre-selected genes with known AD risk association, we found that MAPT (encoding tau protein; star symbol in Fig. 4a ; scatter plot and cortical map in Fig. 4b ) reached the highest level of brain colocalization with the imaging propagation map of tau (tau out-degree hubs map plus tau indegree hubs map; cortical map in Fig. 4b ), whereas CLU (encoding clusterin protein; star symbol in Fig. 4a ; scatter plot and cortical map in Fig. 4d ) reached the highest level of brain colocalization with the imaging propagation map of Aβ (Aβ out-degree hubs map plus Aβ in-degree hubs map; cortical map in Fig. 4d ). Importantly, MAPT (P = 0.006) and CLU (P = 0.018) were the only genes of our pre-selected genetic set that showed significance when contrasting them against the null hypothesis distribution based on the entire protein-coding transcriptome (Fig. 4c,e) . Moreover, MAPT and CLU gene expression levels were not associated with raw standardized uptake value ratio (SUVR) tau and distribution volume ratio (DVR) Aβ intensity maps from the same sample (Fig. 4f) , indicating that the expression of these genes is associated with the regional propagation of tau and Aβ , respectively, and not with SUVR tau or DVR Aβ intensity levels of pathology.
Finally, we further conducted data-driven analyses in addition to the analysis of pre-selected AD risk genes, to identify genes with expression patterns that are spatially correlated with Aβ or tau propagation maps: 354 genes correlated with the tau imaging propagation pattern and 216 genes with the Aβ imaging propagation pattern. Interestingly, 123 genes were correlated with both tau and Aβ imaging propagation patterns ( Fig. 4c ,e; see these three lists of genes along with their putative functions in Supplementary Tables 3-6 ).
Interactome and Gene Ontology analyses of imaging genetic profiles. Next, we investigated the genetic interactions and biological functionality of the 123 genes with expression patterns correlated with both tau and Aβ propagation (Fig. 5a ). We found that the genetic network of these shared genes displayed a dense organization of interactions in which lipid metabolism annotations were the most relevant neuro-related biological process and cellular component functionality ( Fig. 5a ; family-wise error (FWE)-corrected P < 0.05). This interactome analysis showed that lipid metabolism genes-belonging to the common profile of tau and Aβ -interact with other genes such as APOE, which exhibit a central role in genetic network relationships (see the network layout and centrality graph in Fig. 5a ). Then, we performed further exploratory analysis of interactomes and Gene Ontology of genes with expression patterns correlated specifically with tau (Fig. 5b) or Aβ propagation (Fig. 5c ). The network of tau-related genes seemed to yield a dense organization of interactive genes in which neuron and axon organization was the most relevant neuro-related biological process and cellular component functionality ( Fig. 5b ; FWE-corrected P < 0.05). For instance, this interactome analysis showed that genes implicated in microtubule organization, such as CNTN2 (top 1), DPYSL2 (top 3) and MAP1B (top 19), displayed a central role in these genetic interactions (see network layout and centrality graph in Fig. 5b ).
MAPT had a less central role in this network and it did not hold a position among the top 25 most central genes (the centrality graph in Fig. 5b) . Moreover, we found that BACE1 (encoding β -secretase 1)-a gene related to the cleaving of APP-was a relevant interacting gene in this genetic network (see the network layout and centrality graph in Fig. 5b ). The gene network of Aβ -related genes showed a dense organization of interactions in which dendrite and neuron organization annotations arose as the most relevant neurorelated biological process and cellular component functionality ( Fig.  5c ; FWE-corrected P < 0.05). Interestingly, this interactome analysis showed that genes related to transcriptional regulation of APP, such as APBB1 (top 14) and CLU (top 22), interact with proteincoding genes involved in neuronal cytoskeletal organization, such as TUBA1A (top 3) or TUBA4A (top 16) (see the network layout and centrality graph in Fig. 5c ).
Propagation-based staging of tau, Aβ and APOE genotype. In Fig.  6a , we summarize the main neuroimaging transcriptomic findings and contextualize them with our PET approach. Based on this framework in which different AD-related genotypes are expected to differently affect the tau and/or Aβ molecular pathways, we predicted that genes involved in both tau and Aβ genetic interactome profiles (the gray area in Fig. 6a ) would induce a concomitant tau and Aβ vulnerability. To estimate this assumption, we investigated the propagation-based staging and APOE genotyping in SP individuals of our cross-sectional sample for which APOE ε 4 carrier status was available (n = 68; 21 APOE ε 4 + and 47 APOE ε 4 -). We averaged all propagation-based staging scores from Fig. 3 and obtained global scores for individual tau and Aβ burden. Importantly, we found that APOE ε 4 + participants displayed a linear relationship between tau and Aβ load in the respective propagation pathways, whereas APOE ε 4 -participants did not show any such association (Fig. 6b ).
Discussion
What makes specific neuronal systems vulnerable to the accumulation of AD pathology remains a field of intense research. Recent advances in multitracer PET neuroimaging, particularly those targeting tau and Aβ , as well as advances in genetic biomarker research, have provided new, exciting opportunities for studying AD-specific neuronal degeneration and the genetic risk factors that may underlie it. In this study, we used two unique data sets, a HABS sample with flortaucipir-PET and Pittsburgh compound B (PiB)-PET imaging data, and a sample from the AHBA with data of cortical gene expression levels of the human protein-coding transcriptome, to characterize the topological distributions and colocalizations of in vivo tau and Aβ propagation with the expression of certain genes. We found that both tau and Aβ propagation associate to a common genetic profile related to 'lipid metabolism' , whereas tau propagation was related to the MAPT gene and an 'axon-related' genetic profile, and Aβ propagation was related to the CLU gene and a 'dendrite-related' genetic profile. Although we estimated detailed progression patterns using in vivo PET, it is intriguing that a previous study that matched AHBA anatomical annotations to AD regions found an association between MAPT expression and potential vulnerability to tau accumulation as defined by Braak and Braak staging 20 . In addition to the main findings of our study, here, we also developed a novel quantitative approach for the in vivo staging of AD pathology in humans. Thus, overall, we provide an integrative framework for investigating the neurobiological basis of imaging phenotypes in preclinical and clinical AD, as well as phenotype-genotype associations.
Although PET imaging has been able to identify and visualize Aβ protein deposits in the brain for over a decade, high-affinity radiolabels for tau protein have only recently been successfully developed [21] [22] [23] [24] [25] . Flortaucipir, a newly developed tracer for the imaging of tau pathology with PET, binds with high affinity to hyperphosphorylated tau pathology, for example, in regions such as the medial temporal lobe and the associative cortex, and shows potential for the detection of preclinical and clinical AD populations following the classical Braak and Braak neuropathological staging of neurofibrillary tangles 17, 25, 26 . Hence, it is now possible to design comprehensive side-by-side comparisons of tau and Aβ and to study the initial stages and progression of these proteinopathies. Moreover, as tau and Aβ protein depositions are not randomly distributed, but rather exhibit characteristic spatial patterns 2,27-30 that follow large-scale connectivity networks 19, [31] [32] [33] [34] [35] [36] [37] [38] , the study of AD pathology networks has become essential for the understanding of the spatial distribution and potential propagation of the disease.
Previous PET neuroimaging studies have typically overlooked the temporal dimension and network nature of AD-related pathology. Conventional PET imaging analysis techniques are only sensitive to gross changes in signal intensity, ignoring the spatiotemporal or large-scale network relationships that distributed regions may exhibit in their molecular binding affinity. In this study, we provide new in vivo insights regarding network-wise longitudinal changes of tau and Aβ pathology. We developed a novel graph theory approach for detecting propagation pathways of AD pathology and found distinct propagation pathways for tau and Aβ accumulation. In particular, medial/inferior temporal lobe areas projected pathways of tau propagation toward the anterior pole, lateral and posteromedial temporal cortex and orbitofrontal cortex, whereas the PCC projected Aβ toward surrounding areas and the lateral parietal lobe. These findings support the idea that accumulation patterns of pathology evolve beyond local neighborhoods. For instance, the cross-sectional and longitudinal tau data show that temporal lobe pathology progresses distantly toward the orbitofrontal cortex and limbic areas, such as the PCC. Moreover, our results are in accordance with postmortem histopathology characterizations 2, 27, 28, 34, [39] [40] [41] , as well as recent neuroimaging descriptions 42 , and open new avenues for improving current staging methods and interpreting AD-related pathology findings by accounting for observed propagation routes of pathology progression. For instance, out-degree and in-degree hubs in the cerebral cortex can be seen as regions that act as 'givers' or 'receivers' of signal over time, respectively. Here, we found that temporal cortex areas are the main 'giver' regions for tau signal in this regard. The hubness of the temporal lobe out-degree pattern explains the sequential progression of the signal from this area toward locally and distantly connected areas, such as the cingulate cortex. Thus, we speculate that the 'giving' signal property, at least for this temporal region, implies long-distance connectivity toward locations that are the 'receivers' of signal, such as the previously mentioned cingulate area (as seen in the in-degree maps). In this investigation, we developed new approaches to understand how AD-related pathology advances across specific brain systems in the living human brain. We posit that the human brain behaves as a dynamic network, even while, or even when, it undergoes neurodegeneration. The existence of hub cortical areas that drive the time-based or sequential patterns of tau and Aβ accumulation opens up new possibilities for developing more accurate staging methods that may be able to capture the network spreading nature of AD-related pathology.
Pathology studies have shown that precursor proteins, such as APP, α -secretase, β -secretase and γ -secretase, behave discordantly in patients with AD, leading to the accumulation of self-aggregating Aβ 43 . Moreover, the APOE ε 4 allele genotype and other singlenucleotide polymorphisms in ~20 genes-although with less risk intensity-have been associated with late-onset sporadic AD in genome-wide association studies [6] [7] [8] [9] . However, it remains unknown how genetic factors relate to the concrete progression of pathology across neuronal circuits. Thus, in this study, we focused on integrating information from in vivo propagation patterns of tau and Aβ deposits with putative genetic biomarkers expressed in the human cortex, to investigate whether the identified genetic biomarkers support Tau Amyloid  MAPT  APOE  PICALM  BIN1  CLU  CR1  ABCA7  SORL1  PLEKHC1  CD2AP  CD33  APP  PSEN1  PSEN2  CASS4  EPHA1  PTK2B  INPP5D  MEF2C susceptibility for network accumulation of AD pathology. We found that group-level imaging phenotypes of tau and Aβ propagation are associated with a rich set of genes that are expressed in analogous brain regions in the AHBA. These colocalizations suggest that a common background of genes devoted to lipid metabolism may possibly underlie the evolution of both tau and Aβ across specific neural systems 14 . Although the amyloid hypothesis, centered in the triggered and deleterious effects of Aβ deposits, has been the prevailing model used to explain the pathophysiology of AD, Aβ deposits do not correlate well with the clinical course, neuronal dysfunction or with cognitive performance, and anti-Aβ treatments have failed or have shown inconsistencies in altering the course of the disease 44 . Alternatively, others have emphasized the abnormal intraneuronal accumulation of hyperphosphorylated tau as a critical component in explaining the cause of AD. Specifically, postmortem studies have shown better correlation between premortem cognition and tau than Aβ 45 . However, the inter-relationships between Aβ and tau are far from being understood and some neuropathological work points toward tau inducing Aβ 46 . Here, our findings partially support the notion of an interaction between these proteinopathies.
For example, BACE1 appeared as one of the central genes in the tau-related interactome network. However, there may also be other mechanisms at higher levels of integration beyond direct spatial interactions between tau and Aβ . For instance, the set of genes common to both hallmarks of the disease is implicated in lipid metabolism, in which APOE seems to have a central role. Although APOE gene expression was not identified as directly spatially related to neither tau nor Aβ PET progression phenotypes, APOE displayed a critical place in the common interactome network observed in this study. Thus, it is plausible that APOE may influence tau and Aβ accumulation by third parties, generating a functionality that goes beyond its spatial constraints. If we consider that tau and Aβ are end-products of AD neurodegeneration, it is plausible to postulate that genetic variants along different levels of their common pathways (for example, APOE) may lead to the aggregation and co-occurrence of both AD pathology hallmarks, tau and Aβ . In fact, recent findings postulate that ApoE-binding sites include 1,700 gene promoter regions, implicating genes associated with trophic support, programmed cell death, microtubule disassembly, synaptic function and aging 47 , processes in which tau and Aβ have been both extensively implicated. In addition, it is also likely that genetic variants of genes specifically associated with either tau or Aβ molecular pathways may confer susceptibility for a specific or predominant accumulation of one or the other. Our final findings partially support this interpretation, for example, although APOE ε 4 + individuals display concomitant tau and Aβ accumulation, APOE ε 4 -individuals may showcase elevated tau or Aβ accumulation but in a way in which they may be unrelated with one another, suggesting that perhaps other genes considered to be less specific to the common pathway of AD dementia could potentially also be related to the spatially different accumulation patterns of tau or Aβ , and account for the APOE ε 4 -AD cases. Over the past few decades, an intense debate has been sustained between Aβ -centrist and tau-centrist views of AD. Although our study was not designed to validate the Aβ -centrist or the tau-centrist view, it does highlight the existence of specific genetic profiles associated with either tau or Aβ PET phenotypes. More importantly, and away from these two centrist viewpoints, we observed that a common genetic background seems to embrace propagation patterns, both for tau and Aβ . In other words, our findings support that common biological sources may underlie tau and Aβ protein malfunctioning, in which APOE ε 4 + could play a critical role (Fig. 6 ). Thus we believe that now more than ever, AD research is in need of novel approaches that integrate in vivo propagation patterns with individual genetic data to unveil idiosyncratic vulnerabilities associated with the development and trajectory of late-onset sporadic AD.
The detection and combination of in vivo patterns of tau and Aβ propagation with genetic profiles of AD risk will aid the future development of comprehensive approaches for better diagnosis and monitoring of AD, as well as for the evaluation of personalized risk to AD at earlier stages of the disease spectrum. In this study, we characterized the cortical propagation pathways of tau and Aβ pathology in a longitudinal cohort of cognitively normal adult participants and identified some of the genetic underpinnings using in situ information from a transcriptome atlas of cerebral tissue. It is important to note that our investigation only examined a fraction of all possible neuropathological events in AD-related neurodegeneration and focuses on PET data from early stages in which small sample sizes and low PET intensity values may be limitations. However, we believe that our findings offer novel avenues for enhancing the detectability of AD trajectories, for interpreting imaging and genetic information in a more integrated manner and for the future monitoring of novel therapeutic strategies. 48 . Direct genotyping of APOE rs7412 and rs429358 was performed at the Harvard Neurodiscovery Center to derive APOE haplotypes. Participants are originally included if they have a score of 0 on the Clinical Dementia Rating scale, a MMSE score of ≥ 25 and if they perform within education-adjusted norms on the logical memory delayed recall test (> 10 for ≥ 16 years of education, > 6 for 8-15 years of education and > 4 for < 8 years of education). All participants undergo at least one comprehensive medical and neurological evaluation and must not have any medical or neurological disorders at enrollment that could contribute to their cognitive abilities. The presence of clinical depression (Geriatric Depression Scale above 11/30) or other psychiatric illnesses, history of alcoholism, drug abuse, head trauma or a family history of autosomal dominant AD dementia were exclusionary criteria. All participants took part in the study using protocols and informed consent procedures approved by the Partners Human Research Committee at the Massachusetts General Hospital. Further information on study design is available in the Nature Research Reporting Summary.
MRI and PET acquisition and preprocessing procedures. All participants underwent a magnetic resonance imaging (MRI) image acquisition of the whole head on a Siemens 3 Tesla Tim Trio system using a 12-channel phased-array head coil that included a T1-weighted MPRAGE (magnetization-prepared rapid gradient-echo) scan using the following parameters: repetition time (TR) = 6,400 ms, echo time (TE) = 2.8 ms, flip angle = 8°, inversion time (TI) = 900 ms and a voxel size of 1.0 × 1.0 × 1.2 mm. We used SPM12 (Wellcome Centre for Human Neuroimaging, University College London, London, UK; http://www.fil.ion.ucl.ac.uk/spm), running under MATLAB v8.0 (Mathworks Inc.), for image preprocessing and normalization of anatomical T1-weighted MRI volumes. We used the VBM8 toolbox for voxel-based morphometry analysis of the anatomical T1-weighted magnetic resonance images 49 . Briefly, after spatial normalization of all images from native to normalized Montreal Neurological Institute/International Consortium for Brain Mapping (MNI/ICBM) space, images were segmented into gray matter, white matter and cerebrospinal fluid. Then, we selected gray matter-modulated and 10-mm full-width at half-maximum Gaussian kernel smoothed images for further analysis to control for gray matter volume intensity. All participants had two PET imaging acquisitions at the Massachusetts General Hospital PET facility: (i) flortaucipir (also known as 18 F-T807 or 18 F-AV-1451) PET that binds to tau in neurofibrillary tangles and neurites 21 , and (ii) a . The final intensity 18 F-T807 maps were obtained, calculating the SUVR using a cerebellar gray reference region. Conversely, 11 C-PiB PET parameters were as follows: following a transmission scan, 10-15 mCi 11 C-PiB was injected intravenously as a bolus and followed immediately by a 60-min dynamic PET scan in 3D mode (63 image planes, 15.2-cm axial field of view, 5.6-mm transaxial resolution and 2.4-mm slice interval; 69 frames: 12 × 15 s, 57 × 60 s) 17, 50 . PiB retention intensity was expressed as the DVR at each voxel and was calculated using Logan's graphical method, using a cerebellar gray reference region. Corrections for normalization, dead time, random coincidences, scattered radiation and attenuation were performed and each frame was evaluated to verify adequate count statistics and the absence of head motion. Using SPM12, all PET data in native space were co-registered with their corresponding anatomical T1-weighted MRI images and spatially normalized into MNI standard space using the normalization parameters obtained from the T1-weighted MRI normalization. Our processing pipeline also included an outlier detection approach based on the assessment of normally distributed values of each voxel within our sample to ensure that only voxels with a normal continuum range of PET values were entered in the regression analysis 51 ( Supplementary Fig. 2 ). All PET data were downsampled from the normalized space to 8-mm isotropic voxel to study the high-dimensional data without computational limitations.
Directional graph theory regression and statistics.
In contrast to conventional analysis approaches in PET imaging in which only regional intensity is investigated, here, we studied PET signal changes using a novel DGTR approach to investigate network-based changes between regions of the human brain ( Supplementary  Fig. 1a,b ; association matrices and network diagrams). Furthermore, conventional analysis approaches in PET imaging fail to infer network changes and network temporal directionality, as they are not designed to utilize the spatiotemporal PET patterns across different brain systems. Thus, DGTR may provide novel information about network-level stages of accumulation of pathology, as well as information about potential pathways of pathology spread associated with progression of the disease through brain tissue.
In DGTR, we assume that PET imaging data are in proximity to a submanifold and are Gaussian smooth signals on a weighted graph in a discretized approximation, as verified in many relevant works [52] [53] [54] . To that end, we first computed PET-based association matrices (or PET-based connectivity matrices) between all pairs of voxels across the gray matter of the brain, and built group-level network graphs for the cross-sectional samples ( Supplementary Fig. 1a and within time 1 connectivity in Fig. 1c ) and longitudinal study samples ( Supplementary  Fig. 1b and between time 1 and time 2 connectivity in Fig. 1c) . We used a partial correlation approach to calculate intersubject associations of DVR or SUVR values between all pairs of voxels of the brain controlled for MRI atrophy by regressing out the influence of gray matter volume intensities. We then designated seeds based on specific a priori regions. We selected the inferior temporal cortex and PCC owing to their early high-intensity values in PET in vivo studies. These two regions of interest were obtained from our previous studies based on PET neuroimaging independent data sets 17, 26 . We used the PCC and inferior temporal seed-based analysis to compare our PET data with and without PVC adjustment using the extended Müller-Gartner method as previously implemented for FreeSufer 42, 55, 56 . As other seeds may also be relevant in this context, particularly if early histological data are taken into account 45, 46, 49 , we included additional seeds in the analysis, such as the entorhinal cortex and the medial prefrontal cortex (Supplementary Fig. 3) . The entorhinal cortex and medial prefrontal cortex (the medial orbitofrontal cortex and the rostral anterior cingulate cortex) regions of interest were based on the Desikan-Killiany atlas 57 . In the particular case of tau data, we controlled our partial regression analysis not just by regressing out the voxel-level gray matter volume information but also by excluding the signal intensity of the plexus choroideus, which may strongly correlate with the signal intensity of medial temporal lobe structures owing to spatial proximity 17 . Signal from the choroid plexus was removed using the region of interest from the Desikan-Killiany subcortical atlas 57 
.
In the cross-sectional propagation model, the partial correlation coefficient between each brain voxel and the a priori seed region was interpreted as a predictor of pathology propagation 18 . In the longitudinal propagation model, the partial correlation coefficient between each brain voxel and the a priori seed region was interpreted as an observation of pathology propagation. For the particular analysis of the longitudinal study sample, we computed connectivity matrices between time 1 and time 2 (red connectivity in the network diagram; Supplementary Fig. 1b,c) . Following the Supplementary Fig. 1c Once all possible interactions between pairs of voxels in the brain have been calculated, we performed statistical comparisons between connectivity profiles of voxels. Again, given the previous example, we can compare the connectivity profiles of voxel b to determine whether differences exist between the distributions of its partial correlation values across the two temporal conditions: (i) voxel b in time 1 against the rest of the voxels in time 2; and (ii) voxel b in time 2 against the rest of the voxels in time 1. Next, we used the two-tailed paired t-statistic to assess the significance (P) of this comparison per node (equations (2) and (3)):
where s 2 represents the variance of the data; n is the number of voxels; i represents the voxels of the brain from 1 to n; and cdf is the cumulative distribution function to compute the t-statistic.
Next, all within-voxel statistical comparisons between paired conditions were corrected for multiple comparisons to eliminate connectivity profiles that represent false positives by using a false discovery rate correction 58 at a q level of 0.05. Later, all connectivity profiles of false discovery rate-surviving voxels were entered in the next calculation (dark nodes in Supplementary Fig. 1c) , in which we computed the final connectivity scores by subtracting the partial correlation values between conditions (equation (4)):
This approach provided the directional (time-based) connectivity relationships between voxels. For instance, if voxel b signal at time 1 explained voxel d signal at time 2 with a statistically significant greater magnitude than how voxel d signal at time 1 explained voxel b signal at time 2, then a directional connection from voxel b to voxel d was established (out-connectivity from b to d; Supplementary Fig. 1c) . The resulting matrices D of this analysis served as inputs for the subsequent weighted-degree computations. We evaluated the overall degree of each voxel to explain hub-based directional relationships in the longitudinal data-independent from a priori selection of specific seed regions-by calculating the out-weighted degree (WD out ) and the in-weighted degree (WD in ) according to equations (5) and (6), where i and j represent the voxels of the brain:
Of note, seed-based analysis was performed by extracting the connections (cross-sectional) or out-connections (longitudinal) from a priori regions of interest. We investigated the spatial similarity between the cross-sectional predicted and the longitudinal observed maps using a voxel-level linear correlation approach.
Cortical space visualizations of the seed-based and weighted-degree results were generated using Caret software (PALS surface (PALS-B12) 59 ; interpolated algorithm and multifiducial mapping). To increase spatial comparability across PET modalities, the result maps were z-score normalized before visualization.
Subject-level analysis using a propagation-based method. Based on the outdegree and in-degree propagation patterns determined by the DGTR approach, we developed a framework to characterize individualized pathological levels for tau and Aβ in participants. We further hypothesized that subject-level tau and Aβ levels determined by our approach would relate to specific rates of cognitive decline and other clinical features across the clinical spectrum of AD. Despite extensive research, it remains difficult to provide prognoses toward AD progression. There are several reasons for this. Current in vivo staging approaches for tau and amyloid are based on qualitative approximations of a priori regions derived from post-mortem histological studies that suffer from sampling limitations, low spatial resolution level and a lack of temporal information. Moreover, standard classification approaches for Aβ PET imaging rely on broad cortical composite regions of interest, such as the frontal, lateral parietal, lateral temporal and retrosplenial cortices-also known as FLR regions-that help to dichotomize individuals into simple Aβ -positive or Aβ -negative categories. However, this approach simplifies the underlying nature of AD pathology and makes it difficult to investigate the complex relationships between imaging features and clinical or cognitive scores. Recent work has shown that consistent regional staging models for both tau and Aβ can be extrapolated directly from cross-sectional PET imaging data 60, 61 . Here, we expand on these in vivo staging approaches by developing a high spatiotemporal resolution and longitudinal propagation-based method to quantitatively characterize, understand and monitor AD pathology in early phases. This is especially relevant for tau PET imaging, which has been associated with spreading tracer retention in samples ranging from cognitively normal to MCI and to AD individuals, and has been strongly related with cognitive decline 26, 41, 62 . Although we cannot build directional graphs from a subject-level tau or Aβ PET image, we can assume that data from individuals are embedded at the group-level directional graph. Thus, we extracted tau and Aβ PET SUVR and DVR intensities at the individual level using masks from our previous section of out-degree and in-degree propagation pathways (templates created from group-level neuroimaging patterns above two standard deviations (2σ )). We built a propagation-based staging score per each propagation pathway from the in-degree template by extracting their tau or Aβ intensity and multiplying it by the sum of all intensities from the out-degree template. We evaluated the clinical relevance of our method and assessed individual patterns of propagation pathways derived from DGTR by analyzing its relationship with clinical diagnosis (that is, SP versus AD/MCI), as well as with individual neuropsychological profiles of SP individuals, including memory and executive function scores. We used a memory z-scores composite that includes the delayed recall scores of the selective reminding test, the free recall of the free and cued selective reminding test and the delayed recall of the logical memory test 63 . The statistical assessment was carried out using linear regression and two-tailed, unpaired t-test corrected by multiple comparisons.
Brain colocalization analysis between propagation patterns and genetic transcriptome. In this section, we used a prioristic knowledge of AD risk genes, as well as data-driven approaches based on the full genome-wide (protein-coding) transcriptome of the AHBA to delineate the cortical genetic profiles associated with the spread of AD pathology and to investigate the neurobiological role of the genetic-imaging associations. In particular, we used a surface anatomical transformation of the cortical transcription profiles of 20,737 protein-coding genes, based on 58,692 measurements of gene expression in 3,702 brain samples obtained from 6 adult human participants of the AHBA 64 (see Supplementary Table  3 for demographic and brain sample details). This anatomical transformation used mapping of the 6 individual matrices of regional gene expression (gene × MNI coordinate) to 68 prespecified cortical brain regions defined in the DesikanKilliany atlas 57 covering the entire cortex, which enabled intersubject averaging (median values) of the regional gene expression levels. We also converted the hubs maps (sum of out-degree and in-degree hubs maps) obtained from the DGTR section into the Desikan-Killiany atlas space and vectorized both imaging and AHBA transcriptome genetic data. Then, we computed the cortical spatial similarity among imaging and genetic maps using Pearson's correlation of the magnitude of cortical profiles across the Desikan-Killiany areas ( Supplementary  Fig. 1d ). As a first step, we identified from the literature previously described genes that are associated with tau and Aβ processing or that confer risk to clinical AD [6] [7] [8] [9] [10] [11] . These selected candidate genes were: MAPT, APOE, PICALM, BIN1, CLU, CR1, ABCA7, SORL1, PLEKHCI, CD2AP, CD33, APP, PSEN1, PSEN2, CASS4, EPHA1, PTK2B, INPPSD, MEF2C, CUGBPI and MADD. We obtained the spatial cortical similarity (or co-localizations) between our AD-related imaging maps (in vivo tau and Aβ longitudinal propagation maps) and expression maps of each of these 21 AD-related genes. Then, we assessed the statistical meaning of these co-localizations by building null hypothesis distributions with the colocalizations between the observed propagation maps and the entire protein-coding transcriptome (cortical gene expression levels of 20,737 genes). The exact P values for specific colocalizations between imaging patterns and genes were obtained from the corresponding z-scores based on the null distribution. We delineated the cortical genetic profiles associated with the propagation of AD pathology in a data-driven approach, by determining for each PET modality all of the genes of the protein-coding transcriptome that met the statistical significance threshold. We considered 2 standard deviations above the transcriptome mean as the statistically significant level.
Interactome and Gene Ontology analysis. Our first analysis focused on investigating spatial similarity between PET pathology propagation patterns and cortical gene expression of select AD risk genes, providing information about brain pathology-gene expression colocalizations. Next, we investigated whether the data-driven genetic imaging profiles, obtained from the similarity analysis between propagation patterns and the full protein-coding transcriptome, display specific biological functionality. Using interactome and over-representation analysis, we studied genetic interactions among the identified set of genes beyond their spatial co-localizations in the cortex. We identified the role of each gene in the interactome analysis using node-level closeness centrality and relied on knowledge-guided insight to guide our understanding of the biological processes and cellular component functions of genetic profiles, using annotations from Gene Ontology 65 . We used Genemania (http://www.genemania.org) 66 and Cytoscape (www.cytoscape.org) 67 software for the interactome analysis and centrality assessment of our gene query lists, in which the weight of genetic associations was based on a composite gene-gene interaction profile from coexpressions, colocalizations, genetic interactions, pathways, predicted physical interactions and shared protein domains 66 . To avoid any arbitrary threshold when selecting neighborhoods associated to gene sets, we obtained 10 interactome networks per query list using a range of neighborhoods from 10 to 100. We obtained a single interactome network per list by calculating the mean weights of the 10 interactome networks. Finally, we used a binomial test (FWE correction at P < 0.05 level) and select parent terms of > 3-fold in the Gene Ontology over-representation analysis to describe genetic annotation-based functionality Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined.
Our study included three data-sets of tau and amyloid PET images: one cross-sectional (N=69) and two longitudinal (N=19 & N=24) study samples of adult individuals (non-overlapping samples). As our analyses were based on graph regression models, we calculated the sample size of the cross-sectional group based on the power to detect an effect of Cohen's d=0.40 with a power of 0.95 (1-β error probability) and α error probability of 0.05 (software G*Power V3.1.2). This power analysis indicated a minimal sample size of N=63. Therefore our cross-sectional sample employed to predict pathology propagation using voxel-based graphs of PET images were sufficient to detect statistically significant correlations between voxels. The two longitudinal samples of this study were used to confirm and replicate the spatial patterns of pathology propagation predicted at the cross-sectional level. For the longitudinal sample, we included all data available to us with two-years of follow up in both, tau and amyloid, PET modalities.
Data exclusions
Describe any data exclusions.
None of the individual subjects were excluded from the analysis. Our processing pipeline also included an outlier detection approach based on the assessment of normally distributed values of each voxel within our sample to ensure that only voxels with a normal continuum range of PET values were entered in the regression analysis. Supplementary Figure 1 shows our results of pathology propagation of tau and Aβ with and without removing outliers from the processing pipeline.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
To asses the robustness and reproducibility of our findings, we used a graph theory approach to predict at the cross-sectional level, and confirm and replicate at the longitudinal level, the pathways in which cortical tau and Aβ spread and accumulate, using Flortaucipir-and PiB-PET imaging in several groups of adult participants from the Harvard Aging Brain Study. Moreover, we used an independent longitudinal sample to replicate our main findings. Replication attempts were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
The main findings of our study are based on cognitively normal elderly individuals without any experimental categorization. Thus, we believe this point does not apply in our case. In a secondary analysis, we compared a group of elderly controls and Alzheimer's disease participants based on well-established clinical criteria.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
All data was acquired as part of the Harvard Aging Brain Study (HABS). The HABS protocol involves blinded subject identifiers for study participants during data sharing and analysis. As our study is based on cognitively normal elderly individuals without any group allocation/ segregation, we believe this point does not apply in our case.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
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Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided 
Software
Policy information about availability of computer code
Describe the software used to analyze the data in this study.
We used Matlab v8.0 (Mathworks Inc., Natick, MA) for imaging, graph theory and statistical analyses. We used SPM12 (Wellcome Centre for Human Neuroimaging, University College London, London, UK, http://www.fil.ion.ucl.ac.uk/spm), and its VBM8 toolbox, for structural imaging processing. We used Caret v5 software for imaging surface projections. We used Gene Ontology (www.geneontology.org/), Genemania v3.4 (http://www.genemania.org) and Cytoscape v3.4 (www.cytoscape.org) for genetic annotation and interaction analyses.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for providing algorithms and software for publication provides further information on this topic.
Materials and reagents
Policy information about availability of materials
Materials availability
Indicate whether there are restrictions on availability of unique materials or if these materials are only available for distribution by a third party. n/a 9. Antibodies Describe the antibodies used and how they were validated for use in the system under study (i.e. assay and species). n/a
